Replies to post #360952 on Amarin Corp Plc (AMRN)

[bidmark]

I think we all suffer from the “it’ll sell itself” hype that several posters promoted for years. In the Piper Sandler chat, Yasmin asked Karim about the difference between launching in the USA vs. Europe. The main difference, he explained, is that Vascepa had been around for a number of years in the US and in Europe it was pretty much unknown - so marketing a new indication vs. a new start. She didn’t ask him which he preferred!

[rosemountbomber]

“ Are we all expecting Vascepa to gain traction faster that what is realistic? “

I know that some here in the past had that expectation, but hopeful we all have more realistic expectations now. Of course part of the sluggishness is due to generics (US) and Covid (everywhere).

Quite a while back I made reference to something I saw or read (could have been 60 minutes) where it indicated that advances in treatment often take years (like 10 or more) to get fully adopted down to the doc-patient relationship.

Add that to some of the special quirky circumstances with Vascepa, like some docs telling their patients to just go get fish oil, and we must not forget on again off again tier jockeying by the insurers.

Hopefully some of those won’t be present in the EU and ROW (i.e. generics and insurers) so it will be primarily getting docs to prescribe.